First-day pop for Allogene after year's largest biotech IPO on NASDAQ

Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Wednesday in the largest IPO by a biotech on NASDAQ thus far in 2018. The company gained $7 (39%) to $25 in its first trading day Thursday.

Allogene sold 18 million shares at $18, the top of its proposed

Read the full 573 word article

User Sign In